Analysts Set Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Target Price at $16.56

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have earned a consensus rating of “Buy” from the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and three have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $16.5556.

Several equities analysts have recently issued reports on IVA shares. Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Finally, Cantor Fitzgerald assumed coverage on shares of Inventiva in a research note on Friday, July 17th. They set an “overweight” rating for the company.

Hedge Funds Weigh In On Inventiva

A number of institutional investors have recently added to or reduced their stakes in the company. Creative Planning acquired a new position in shares of Inventiva during the 2nd quarter worth about $32,000. Virtu Financial LLC acquired a new position in shares of Inventiva in the fourth quarter valued at approximately $60,000. XTX Topco Ltd bought a new position in Inventiva during the 4th quarter worth $84,000. Cerity Partners LLC bought a new position in Inventiva during the fourth quarter worth about $93,000. Finally, NewEdge Advisors LLC bought a new position in shares of Inventiva during the third quarter worth approximately $116,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Stock Down 1.1%

Shares of IVA stock opened at $4.46 on Friday. Inventiva has a 52-week low of $2.85 and a 52-week high of $7.98. The firm’s 50 day moving average price is $4.25 and its two-hundred day moving average price is $5.31.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.